Pharmaceutical company Shire U.S. Inc. is close to resolving a lawsuit accusing it of illegally trying to delay sales of generic versions of Adderall XR, a popular drug prescribed to treat attention-deficit hyperactivity disorder (Barba v. Shire US Inc., S.D. Fla., 13-2115, motion filed 2/11/16).
The company reached a settlement in principle with consumer plaintiffs, following private mediation, according to court papers. Terms of the deal weren’t disclosed.
“That’s confidential until we put pen to paper,” Conlee Whiteley, an attorney for the plaintiffs told Bloomberg BNA on Feb. 12.
A Shire spokeswoman declined to comment on the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.